Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay
About this episode
This episode features an interview with Dr. Rana R McKay discussing various aspects of androgen deprivation therapy for prostate cancer.
Featuring an interview with Dr Rana R McKay, including the following topics: Prostate Cancer Working Group (PCWG4) revised terminology (0:00) Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17) Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06) Takeaways from the Phase III EMBARK study (19:36) Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20) Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24) CME information and select publications
More episodes of Prostate Cancer Update
- For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress
- Urothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances
- Prostate Cancer — Fifth Annual National General Medical Oncology Summit
- Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
- Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Explore listener stats, chart rankings, contacts and more on the Prostate Cancer Update podcast page.